RNA Therapy Reverses Decline in First ALS Patient — A Neurological First
A man with a rare inherited form of amyotrophic lateral sclerosis showed meaningful clinical improvement after a personalised gene-targeting RNA therapy — the first reported case of an RNA treatment reversing neurological decline in a living ALS patient, reported in Nature.
- The treatment targets the specific genetic mutation driving the patient's ALS subtype rather than a shared disease mechanism, making it inherently personalised
- RNA therapies have already succeeded in spinal muscular atrophy via Spinraza; this case indicates the same approach can reach inherited ALS variants in the clinic
- The patient is a single individual; regulatory approval requires clinical trials for each mutation subtype — the pathway to broad deployment is narrow and expensive